Rhythm history, structural heart concerns, syncope, family history, electrolyte status, and QT-related findings can change the risk picture.
Ibogaine eligibility context
Screening Checklist
A structured way to understand who may be screened out, deferred, or referred for further review before ibogaine or noribogaine exposure is considered.
Screening is not a promise of safety and it is not a diagnosis. It is a risk-filtering process shaped by cardiac findings, medications, psychiatric history, laboratory results, pregnancy considerations, age, and whether the setting can monitor and respond to complications.
01 / Review domains
The questions a checklist is trying to answer
There is no universal private-program checklist, but responsible evaluation generally asks whether a foreseeable risk can be identified, reduced, monitored, and treated if it occurs. The public overview of ibogaine screening risks and eligibility can help frame why those questions matter before any decision is made.
Prescription, over-the-counter, and non-prescribed substances may create interaction, withdrawal, or additive rhythm-risk concerns.
Hepatic, renal, metabolic, and electrolyte findings may prompt more assessment, postponement, or exclusion.
A meaningful screen also asks what observation, escalation, and emergency response the actual setting can provide.
Cardiac
Medical / labs
Psychiatric
Interactions
02 / Common exclusion domains
Findings that commonly trigger a closer stop
-
Cardiac and ECG concernsIbogaine has been associated with QTc prolongation, a change linked with risk for dangerous ventricular arrhythmias. The clinical context for QT interval risk and abnormal rhythms helps explain why ECG review, electrolytes, and a cardiac history matter.
-
Hepatic, renal, or electrolyte abnormalitiesAbnormal liver, kidney, potassium, magnesium, or related results can change drug handling and arrhythmia risk. A result may prompt repeat testing or specialist review rather than a simple yes-or-no answer.
-
Psychiatric instabilityA history of psychosis, mania, acute suicidality, severe agitation, or an unstable psychiatric condition can require formal evaluation. Screening has to distinguish documented history from current stability and support needs.
-
Drug interactions and recent substance useMedication reconciliation matters because some medicines affect cardiac conduction, metabolism, seizure threshold, blood pressure, or withdrawal risk. A full list should include supplements and recently stopped substances.
03 / Decision workflow
Temporary deferral is different from permanent exclusion
A screen may pause the process while an issue is clarified. It may also identify a risk that cannot be reasonably managed in a given environment. The terminology varies, but the practical distinction is important.
Incomplete or concerning data
Examples can include an unclear medication history, a borderline ECG, missing laboratory work, or symptoms that need a clinician’s assessment.
Risk may be modifiable
A pause can allow a prescribing clinician, cardiology professional, or other relevant specialist to review a finding and determine whether it has been addressed.
Risk cannot be responsibly contained
Some cardiac, psychiatric, pregnancy-related, age-related, or monitoring limitations may make exposure unsuitable for a particular research protocol or treatment setting.
“A more detailed screen does not make an investigational intervention routine; it makes the limits of the decision more visible.”
04 / Setting comparison
The same person can face different thresholds in different settings
Eligibility decisions are not portable. A study protocol, a hospital research unit, and a private provider may use different inclusion rules, available personnel, monitoring equipment, escalation pathways, and tolerance for unresolved uncertainty.
Protocol first
Research protocols commonly set defined eligibility criteria, required testing, exclusions, and follow-up procedures. The ClinicalTrials.gov registry shows how trial records document study-specific criteria and investigational status.
Monitoring capacity
Hospital-based research may have more direct access to diagnostic services and emergency escalation, but this does not erase the importance of exclusion criteria or protocol limits.
Ask what is verifiable
Policies, testing depth, and emergency resources can vary. Anyone comparing ibogaine options in Mexico should distinguish descriptions of screening from independently verified clinical capability.
Limits become decisive
When ECG review, laboratory assessment, continuous observation, and emergency response are absent, the ability to identify or manage foreseeable risk is substantially constrained.
05 / Reader guidance
Bring complete information to any independent medical conversation
Useful records commonly include a current medication list with doses and timing, substance-use history, prior ECGs if available, cardiac symptoms or diagnoses, family history of sudden death or rhythm disorders, relevant laboratory results, and psychiatric treatment history. These records can help a qualified clinician identify questions that deserve a formal answer.
The FDA has not approved ibogaine for treatment use in the United States; its place in drug research and regulation is better understood through the FDA drug development and approval process. The pharmacology and naming context for ibogaine’s investigational profile should not be mistaken for a personal risk assessment.
06 / Practical questions
Screening context, without false certainty
-
Does a screening exclusion always mean permanent exclusion?
No. A finding can lead to temporary deferral while a medication is reviewed, a laboratory result is repeated, or a specialist evaluates a concern. Other findings may make exposure inappropriate in a particular setting. The distinction is explored further in when someone might be deferred.
-
What information is typically relevant before a screening decision?
Programs and research settings may consider a complete medication and substance history, ECG findings, laboratory work, medical history, psychiatric history, pregnancy status where relevant, and the capacity for continuous monitoring and emergency response. Broader background on how Qadence approaches those safety limits is available in the organization’s approach to risk context.
-
Why do cardiac concerns receive so much attention?
Ibogaine-associated QTc prolongation and arrhythmia concerns make cardiac review central to screening. For a more focused explanation of the language around rhythm risk, see the cardiac risk overview; a person’s own ECG interpretation belongs with an appropriately qualified clinician.
-
Can online information determine whether someone qualifies?
No. Online material can organize questions, not determine eligibility. For context beyond this checklist, perspectives on reported ibogaine benefits, an ibogaine and brain-deaging discussion, and ibogaine market coverage should be read with particular care because none replaces individualized clinical evaluation.
-
Does a treatment location change the basic safety questions?
No. Location does not remove the need for careful medical, psychiatric, medication, and monitoring review. Conversations about European ibogaine treatment settings or the broader history documented by the ibogaine documentary project are not evidence that a particular person is eligible or that a setting can manage every complication.